PURPOSE: To clarify the efficacy of a right-sided video-assisted thoracoscopic extended thymectomy (RtVATET) as a surgical alternative for myasthenia gravis (MG) and to determine the optimal timing for a thymectomy. METHODS: Thirty-three patients who underwent RtVATET in two institutes were enrolled in this study. Another 66 paired, traditional trans-sternal extended thymectomy (TET) patients from the registered database were used to compare these two surgical modalities for MG. RESULTS: Mean blood loss was 88.5 ml in RtVATET and 226.8 ml in TET group patients (P < 0.001). Mean operation duration was 207.3 min for RtVATET and 172.8 min for TET patients (P = 0.003). Complete stable remission (CSR) rates and total improvement rates for the RtVATET and TET patients were 42.4% vs 60.6% (P = 0.087) and 87.9% vs 90.1% (P = 0.637), respectively. Furthermore, when we focused on the minor grades (classes I and IIa), TET groups showed significantly better CSR than the RtVATET groups (P = 0.012), but there was no statistically significant difference for the more severe grades (classes IIb and III, P = 0.827). CONCLUSION: Both RtVATET and TET are effective for treating MG, although this study does indicate an advantage for TET. We suggest that a thymectomy should therefore be performed earlier, or that the procedures should be extensive enough to remove all of the tissue that contains thymic tissue.
PURPOSE: To clarify the efficacy of a right-sided video-assisted thoracoscopic extended thymectomy (RtVATET) as a surgical alternative for myasthenia gravis (MG) and to determine the optimal timing for a thymectomy. METHODS: Thirty-three patients who underwent RtVATET in two institutes were enrolled in this study. Another 66 paired, traditional trans-sternal extended thymectomy (TET) patients from the registered database were used to compare these two surgical modalities for MG. RESULTS: Mean blood loss was 88.5 ml in RtVATET and 226.8 ml in TET group patients (P < 0.001). Mean operation duration was 207.3 min for RtVATET and 172.8 min for TETpatients (P = 0.003). Complete stable remission (CSR) rates and total improvement rates for the RtVATET and TETpatients were 42.4% vs 60.6% (P = 0.087) and 87.9% vs 90.1% (P = 0.637), respectively. Furthermore, when we focused on the minor grades (classes I and IIa), TET groups showed significantly better CSR than the RtVATET groups (P = 0.012), but there was no statistically significant difference for the more severe grades (classes IIb and III, P = 0.827). CONCLUSION: Both RtVATET and TET are effective for treating MG, although this study does indicate an advantage for TET. We suggest that a thymectomy should therefore be performed earlier, or that the procedures should be extensive enough to remove all of the tissue that contains thymic tissue.
Authors: A Jaretzki; A S Penn; D S Younger; M Wolff; M R Olarte; R E Lovelace; L P Rowland Journal: J Thorac Cardiovasc Surg Date: 1988-05 Impact factor: 5.209
Authors: Amy J Wagner; Raul A Cortes; Jonathan Strober; Erich J Grethel; Matthew S Clifton; Michael R Harrison; Diana L Farmer; Kerilyn K Nobuhara; Hanmin Lee Journal: J Pediatr Surg Date: 2006-01 Impact factor: 2.545
Authors: G B Bulkley; K N Bass; G R Stephenson; M Diener-West; S George; P A Reilly; R R Baker; D B Drachman Journal: Ann Surg Date: 1997-09 Impact factor: 12.969
Authors: Joseph B Shrager; Derek Nathan; Clayton J Brinster; Omair Yousuf; Abraham Spence; Zhen Chen; Larry R Kaiser Journal: Ann Thorac Surg Date: 2006-11 Impact factor: 4.330
Authors: Nicholas R Hess; Inderpal S Sarkaria; Arjun Pennathur; Ryan M Levy; Neil A Christie; James D Luketich Journal: Ann Cardiothorac Surg Date: 2016-01
Authors: Jia-Xin Xu; Kai Qian; Yi Deng; Yan-Yan Zheng; Chun-Mei Ou; Jie Liu; Li-Hong Jiang Journal: Int J Med Robot Date: 2021-09-24 Impact factor: 2.483
Authors: Sharifah A Othman; Othman Y AlFrayyan; Zeead M AlGhamdi; Fahd Makhdom; Yasser AlJehani; Hatem Y Elbawab; Mohamed El-Shawarby Journal: Am J Case Rep Date: 2020-08-03